Skip to main content

Michael Jerman

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Michael Jerman

Michael Jerman is recorded as Board Member at Inhibitor Therapeutics, Inc. (INTI). Inhibitor Therapeutics, Inc. reported in an 8-K filed September 18, 2026 that Michael Jerman was appointed Director, effective September 15, 2026. Telomir Pharmaceuticals, Inc. reported in an 8-K filed November 21, 2024 that Michael Jerman resigned as Chair of the Audit Committee of the Company, effective November 18, 2024. Telomir Pharmaceuticals, Inc. reported in an 8-K filed November 21, 2024 that Michael Jerman resigned as member of the Board of Directors of the Company, effective November 18, 2024.

“Francis E. O'Donnell, Samuel J. Sears, Niraj Vasisht, Michelle Yanez, Michael Jerman and Ronald E. Osman were each elected to serve on the Board of Directors (the "Board") for a one-year term that expires at the 2027 Annual Meeting of Stockholders, or until their earlier death, resignation or removal and their successors are elected and qualified.”
Inhibitor Therapeutics, Inc. Form 8-K, filed September 18, 2026 · Read the filing
“On November 18, 2024, Telomir Pharmaceuticals, Inc. (the "Company") received written notice of resignation from Michael Jerman resigning, with immediate effect, from his positions a member of the Board of Directors of the Company (the "Board") and as Chair of the Audit Committee of the Company (the "Audit Committee").”
Telomir Pharmaceuticals, Inc. Form 8-K, filed November 21, 2024 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Leadership on record at Inhibitor Therapeutics, Inc.

Other people whose current roles at this company are on record from its filings.

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.